A practical reference on GHRH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-05. Anything still debated is marked as such rather than presented as settled.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
From June 2023 to April 2024, Serbian television presenter Bojana Janković (née Nikolić), known for hosting the show City, posted to the internet forum Bluelight that she was bedridden with symptoms consistent with neuroleptic-induced deficit syndrome after receiving six depot injections of paliperidone palmitate (four shots of Invega Sustenna and two shots of Invega Trinza). She wrote: "My main problem is 0 motivation, low energy and anhedonia. Also i have cognitive issues. Beddriden mostly..." The injections were prescribed by her private psychiatrist and friend around the time of her divorce from Ognjen Janković, a member of the hip-hop group Beogradski Sindikat. She died by suicide in Belgrade on April 19, 2024, aged 46.
== External links == AGSD. - Association for Glycogen Storage Disease. A US-based non-profit, parent and patient oriented support group dedicated to promoting the best interest of all the different types of glycogen storage disease. AGSD-UK - Association for Glycogen Storage Disease (UK). A UK-based charity which helps individuals and families affected by Glycogen Storage Disease by putting people in contact, providing information and support, publishing a magazine and holding conferences, workshops, courses and family events. IamGSD - International Association for Muscle Glycogen Storage Disease. A non-profit, patient-led international group encouraging efforts by research and medical professionals, national support groups and individual patients worldwide. IPA - International Pompe Association. (Pompe Disease is also known as GSD-II). A non-profit, federation of Pompe disease patient's groups world-wide. It seeks to coordinate activities and share experience and knowledge between different groups. EUROMAC - EUROMAC is a European registry of patients affected by McArdle Disease and other rare neuromuscular glycogenoses. CoRDS - Coordination of Rare Diseases at Sanford (CoRDS) is a centralized international patient registry for all rare diseases. They work with patient advocacy groups, including IamGSD, individuals and researchers. CORD - Canadian Organization for Rare Disorders (CORD) is a Canadian national network for organizations representing all those with rare disorders.
The rate of deposition of this radioisotope is weather-dependent. Radon concentrations found in natural environments are much too low to be detected by chemical means. A 1,000 Bq/m3 (relatively high) concentration corresponds to 0.17 picogram per cubic meter (pg/m3). The average concentration of radon in the atmosphere is about 6×10−18 molar percent, or about 150 atoms in each milliliter of air. The radon activity of the entire Earth's atmosphere originates from only a few tens of grams of radon, consistently replaced by decay of larger amounts of radium, thorium, and uranium.
Thus, iodine-131 is increasingly less employed in small doses in medical use (especially in children), but increasingly is used only in large and maximal treatment doses, as a way of killing targeted tissues (i.e. therapeutic use). Iodine-131 can be "seen" by nuclear medicine imaging techniques (e.g., gamma cameras) whenever it is given for therapeutic use, since it is a strong emitter of gamma radiation. However, since the beta radiation causes tissue damage without contributing to any ability to see or "image" the isotope, other less-damaging radioisotopes of iodine such as iodine-123 (see isotopes of iodine) are preferred in situations when only imaging is wanted. The isotope 131I is still occasionally used for purely diagnostic (i.e., imaging) work, due to its low expense compared to other iodine radioisotopes. No increase in thyroid cancer has been seen from the small medical imaging doses of 131I. The low-cost availability of 131I, in turn, is due to the relative ease of creating 131I by neutron bombardment of natural tellurium in a nuclear reactor, then separating 131I out by various simple methods (i.e., heating to drive off the volatile iodine). By contrast, other iodine radioisotopes are usually created by far more expensive techniques, starting with cyclotron radiation of capsules of pressurized xenon gas. Iodine-131 is also one of the most commonly used gamma-emitting radioactive industrial tracer.
== Second round proper == The draw for the second round was made on BBC Two on 7 November 2022 by Jermaine Beckford and Mickey Thomas at the Racecourse Ground in Wrexham, and consisted of the 40 winners from the previous round. The round contained one team from the seventh tier, Alvechurch, who defeated EFL League One club Cheltenham Town in the first round.
Sources: en.wikipedia.org
The concentration of erbium in the Earth’s crust is about 2.8 mg/kg and in seawater 0.9 ng/L. (Concentration of less abundant elements may vary with location by several orders of magnitude making the relative abundance unreliable). Like other rare earths, this element is never found as a free element in nature but is found in monazite and bastnäsite ores. It has historically been very difficult and expensive to separate rare earths from each other in their ores but ion-exchange chromatography methods developed in the late 20th century have greatly reduced the cost of production of all rare-earth metals and their chemical compounds. The principal commercial sources of erbium are from the minerals xenotime and euxenite, and most recently, the ion adsorption clays of southern China. Consequently, China has now become the principal global supplier of this element. In the high-yttrium versions of these ore concentrates, yttrium is about two-thirds of the total by weight, and erbia is about 4–5%. When the concentrate is dissolved in acid, the erbia liberates enough erbium ion to impart a distinct and characteristic pink color to the solution. This color behavior is similar to what Mosander and the other early workers in the lanthanides saw in their extracts from the gadolinite minerals of Ytterby.
== Use in biotechnology == Fat-free powdered milk is used as a saturating agent to block nonspecific binding sites on supports like blotting membranes (nitrocellulose, polyvinylidene fluoride (PVDF) or nylon), preventing binding of further detection reagents and subsequent background. It may be referred as Blotto. The major protein of milk, casein, is responsible for most of the binding site saturation effect.
Hemoglobin, erythrocruorin, and chlorocruorin are all globins, iron-heme proteins with a common core. Their color comes from the absorption spectra of heme with Fe2+. Erythrocruorin and chlorocruorin are closely related giant globins found used by some invertebrates. Chlorocruorin has a special heme group, giving it different colors. Any of various coloured conjugated proteins, such as hemoglobin, occur in living organisms and function in oxygen transfer in cellular respiration.
First, it exists to exploit the author-pays Open Access model to generate revenue, and second, it serves as an easy place for foreign (chiefly Chinese) authors to publish overseas and increase their academic status." He acknowledges that its fees are relatively low, describing this as "a strategy that increases article submissions," and that "it has attracted some quality article submissions. Nevertheless, it is really a vanity press." Further controversy was generated by a mass resignation of the editorial board of one of the company's journals, Advances in Anthropology, in 2013. According to the former editor-in-chief, Fatimah Jackson, it was motivated by failures to include the editorial board in the journal's review process, and by "consistent and flagrant unethical breaches by the editorial staff in China", for whom publishing the journal "was only about making money." According to Beall, this was the first mass resignation from an open-access journal. In 2021 Cabells' Predatory Reports described SCIRP as a "well-known predatory publisher". In the Norwegian Scientific Index, the publisher and all of its journals have a rating of 0 (non-academic). An academic study published in 2022 stated that SCIRP was "widely known to host 'fake journals'".
=== Transporter/receptor classification === GluT type: these express glutamate transporters (EAAT1/SLC1A3 and EAAT2/SLC1A2) and respond to synaptic release of glutamate by transporter currents. The function and availability of EAAT2 is modulated by TAAR1, an intracellular receptor in human astrocytes. GluR type: these express glutamate receptors (mostly mGluR and AMPA type) and respond to synaptic release of glutamate by channel-mediated currents and IP3-dependent Ca2+ transients.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.